Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy
Enrolling By Invitation
18 years - 99 years
All
Phase
3
99999 participants needed
1 Location
Brief description of study
This trial compares nephrectomy (surgery to remove a kidney or part of a kidney) with nivolumab to the usual approach of nephrectomy followed by standard post-operative follow-up and monitoring, in treating patients with kidney cancer that is limited to a certain part of the body (localized). Nivolumab is a drug that may help stimulate the immune system to attack any cancer cells that may remain after surgery. The addition of nivolumab to the usual surgery could prevent the cancer from returning. It is not yet known whether nivolumab and nephrectomy is more effective than nephrectomy alone in treating patients with kidney cancer.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Kidney Cancer
-
Age: 18 years - 99 years
-
Gender: All
Male or Female, Age 18 or Older, Patients must have a renal mass
Updated on
04 Aug 2024.
Study ID: 826834
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245
